Hospital
Page Hospital
Page Hospital was paid $15.30M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoPAGE HOSPITAL
PAGE, AZ 86040
PAGE, AZ 86040
33aNPI1578515789assigned 05/16/2006
33bProvider typeCritical Access Hospital
28Total paid$15.30M
24GClaims170,489
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arizona
Rank by total paid#4 of 15
Median peer was paid$6.92M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,028 | $2.38M | |
| 2019 | 24,960 | $2.34M | |
| 2020 | 20,660 | $2.03M | |
| 2021 | 25,158 | $2.31M | |
| 2022 | 27,951 | $2.47M | |
| 2023 | 25,043 | $2.06M | |
| 2024incomplete | 18,689 | $1.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 13,860 | 12,857 | $4.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 9,009 | 8,129 | $3.98M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 4,469 | 4,040 | $2.22M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.9% | 1,189 | 1,036 | $1.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.6% | 6,763 | 6,222 | $1.32M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 1,756 | 1,454 | $536K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 7,177 | 2,126 | $327K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 337 | 300 | $215K |
| G0378 | Hospital observation service, per hour | <1% | 574 | 217 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,345 | 1,157 | $57K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 84 | 71 | $56K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,869 | 2,256 | $29K |
108 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,223 | $26K |
| 80053 | Comprehensive metabolic panel | <1% | 10,263 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,995 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,143 | $17K |
| J3490 | Unclassified drugs | <1% | 6,714 | $15K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 82 | $10K |
| 73630 | <1% | 244 | $9K | |
| 73130 | <1% | 242 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,437 | $8K |
| 97162 | <1% | 90 | $8K | |
| 73610 | <1% | 226 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,092 | $7K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,819 | $6K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 33 | $5K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 138 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 150 | $4K |
| 73562 | <1% | 139 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,004 | $4K |
| A9270 | Non-covered item or service | <1% | 3,107 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,785 | $4K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 6,040 | $4K |
| 76801 | <1% | 45 | $3K | |
| 12001 | <1% | 27 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,866 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 51 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 105 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 16 | $2K |
| 73030 | <1% | 29 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,183 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,887 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,699 | $1K |
| 86901 | <1% | 14 | $1K | |
| 81001 | <1% | 4,928 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,954 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 63 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 310 | $970.40 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,260 | $962.89 |
| 87631 | <1% | 498 | $955.51 | |
| 83880 | <1% | 357 | $929.63 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 29 | $924.88 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 445 | $903.61 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 309 | $661.31 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 77 | $611.00 |
| 74018 | <1% | 15 | $559.42 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,624 | $520.78 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $479.16 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,651 | $471.54 |
| 82947 | <1% | 2,028 | $414.95 | |
| 73080 | <1% | 13 | $408.78 | |
| 87081 | <1% | 186 | $391.22 | |
| 84484 | <1% | 3,405 | $330.07 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 274 | $302.55 |
| 85610 | <1% | 2,151 | $294.90 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 438 | $279.51 |
| 83690 | <1% | 3,184 | $220.46 | |
| 84702 | <1% | 99 | $216.84 | |
| 86140 | <1% | 442 | $216.55 | |
| 97161 | <1% | 38 | $215.58 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 84 | $195.04 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 363 | $190.70 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 221 | $159.62 |
| 80306 | <1% | 817 | $109.90 | |
| 80305 | <1% | 888 | $103.96 | |
| 96367 | <1% | 61 | $101.34 | |
| 83605 | <1% | 2,079 | $92.95 | |
| 85027 | <1% | 602 | $83.45 | |
| 83735 | <1% | 3,019 | $82.32 | |
| 81025 | <1% | 2,264 | $76.38 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 26 | $64.12 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 655 | $58.85 |
| 85379 | <1% | 27 | $53.46 | |
| 80320 | <1% | 2,427 | $46.34 | |
| 87040 | <1% | 668 | $31.30 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,312 | $27.64 |
| 87088 | <1% | 1,013 | $22.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 878 | $13.89 |
| 81003 | <1% | 1,112 | $12.17 | |
| 85730 | <1% | 164 | $5.65 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 73 | $5.07 |
| 84100 | <1% | 131 | $4.24 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,075 | $0.02 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 133 | $0.00 |
| 83615 | 0% | 60 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 97 | $0.00 |
| 87807 | 0% | 353 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 492 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 44 | $0.00 |
| 96376 | 0% | 268 | $0.00 | |
| 87077 | 0% | 228 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 58 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 40 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 63 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 15 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 13 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 24 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 15 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 12 | $0.00 |
| 84703 | 0% | 54 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 12 | $0.00 |
| 87186 | 0% | 102 | $0.00 | |
| 90715 | 0% | 105 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 91 | $0.00 |
| 87210 | 0% | 13 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 45 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 45 | $0.00 |
| 84145 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPARKER, RALPH (CEO)
Parent organizationBANNER HEALTH
| Provider | Location | Paid |
|---|---|---|
| Page Hospital | Page, AZ | $666K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.